Point-of-care testing in diabetes management

Open access

Abstract

The prevalence of diabetes mellitus (DM) has rapidly increased over the last decades, reaching epidemic magnitudes, particularly in lowand middle-income countries. Point-of-care (POC) technology enables decision making near or at the site of patient care. Portable blood glucose meters and HbA1c testing are used by the healthcare provider and millions of patients with diabetes to monitor the safety and effectiveness of the diabetes treatment. However, POC capillary blood glucose and POC HbA1c testing are not recommended for diabetes diagnosis. Rather, they have been used for screening diabetes in lowand middle-income countries to decrease the disease burden.

1. International Diabetes Federation Diabetes Atlas, Eighth edition. 2017. http://diabetesatlas.org/resources/2017-atlas.html

2. American Diabetes Association. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2018. Diabetes Care. 2018 Jan;41(Suppl 1):S13-S27. DOI: 10.2337/dc18-S002

3. Albers JW, Herman WH, Pop-Busui R, Feldman EL, Martin CL, Cleary PA, et al. Effect of prior intensive insulin treatment during the Diabetes Control and Complications Trial (DCCT) on peripheral neuropathy in type 1 diabetes during the Epidemiology of Diabetes Interventions and Complications (EDIC) Study. Diabetes Care. 2010 May;33(5):1090-6. DOI: 10.2337/dc091941

4. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000 Aug 12;321(7258):405-12. DOI: 10.1136/bmj.321.7258.405

5. Gillett MJ. International Expert Committee report on the role of the A1c assay in the diagnosis of diabetes: Diabetes Care 2009; 32(7): 1327-1334. Clin Biochem Rev. 2009 Nov;30(4):197-200.

6. Larsson A, Greig-Pylypczuk R, Huisman A. The state of point-of-care testing: a European perspective. Ups J Med Sci. 2015 Mar;120(1):1-10. DOI: 10.3109/03009734.2015.1006347

7. Portero McLellan KC, Wyne K, Villagomez ET, Hsueh WA. Therapeutic interventions to reduce the risk of progression from prediabetes to type 2 diabetes mellitus. Ther Clin Risk Manag. 2014 10:173-88.

8. Saldarriaga EM, Vodicka E, La Rosa S, Valderrama M, Garcia PJ. Point-of-Care Testing for Anemia, Diabetes, and Hypertension: A Pharmacy-Based Model in Lima, Peru. Ann Glob Health. 2017 Mar Apr;83(2):394-404. DOI: 10.1016/j.aogh.2017.03.514

9. American Diabetes Association. Glycemic Targets: Standards of Medical Care in Diabetes-2018. Diabetes Care. 2018 Jan;41(Suppl 1):S55-S64. DOI: 10.2337/dc18-S006

10. Bergenstal RM, Gavin JR, 3rd, Global Consensus Conference on Glucose Monitoring P. The role of self-monitoring of blood glucose in the care of people with diabetes: report of a global consensus conference. Am J Med. 2005 Sep;118(Suppl 9A):1S-6S. DOI: 10.1016/j.amjmed.2005.07.055

11. Polonsky WH, Fisher L, Schikman CH, Hinnen DA, Parkin CG, Jelsovsky Z, et al. Structured self-monitoring of blood glucose significantly reduces A1C levels in poorly controlled, noninsulin-treated type 2 diabetes: results from the Structured Testing Program study. Diabetes Care. 2011 Feb;34(2):262-7. DOI: 10.2337/dc10-1732

12. Virdi N, Daskiran M, Nigam S, Kozma C, Raja P. The association of self-monitoring of blood glucose use with medication adherence and glycemic control in patients with type 2 diabetes initiating non-insulin treatment. Diabetes Technol Ther. 2012 Sep;14(9):790-8. DOI: 10.1089/dia.2012.0047

13. Grant RW, Huang ES, Wexler DJ, Laiteerapong N, Warton ME, Moffet HH, et al. Patients who self-monitor blood glucose and their unused testing results. Am J Manag Care. 2015 Feb 1;21(2):e119-29.

14. Rajendran R, Rayman G. Point-of-care blood glucose testing for diabetes care in hospitalized patients: an evidence-based review. J Diabetes Sci Technol. 2014 Nov;8(6):1081-90. DOI: 10.1177/1932296814538940

15. ISO 15197. In vitro diagnostic test systems Requirements for blood-glucose monitoring systems for self-testing in managing diabetes mellitus. 2013. https://www.iso.org/standard/54976.html

16. Food and Drug Administration. Self-Monitoring Blood Glucose Test Systems for Over-the-Counter Use 2016. https://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/UCM380327.pdf

17. Food and Drug Administration. Blood Glucose Monitoring Test Systems for Prescription Point-of-Care Use 2016. https://www.fda.gov/downloads/ucm380325.pdf

18. Ekhlaspour L, Mondesir D, Lautsch N, Balliro C, Hillard M, Magyar K, et al. Comparative Accuracy of 17 Point-of-Care Glucose Meters. J Diabetes Sci Technol. 2017 May;11(3):558-66. DOI: 10.1177/1932296816672237

19. Klonoff DC, Parkes JL, Kovatchev BP, Kerr D, Bevier WC, Brazg RL, et al. Investigation of the Accuracy of 18 Marketed Blood Glucose Monitors. Diabetes Care. 2018 Aug;41(8):1681-8. DOI: 10.2337/dc17-1960

20. Rebel A, Rice MA, Fahy BG. Accuracy of point-of-care glucose measurements. J Diabetes Sci Technol. 2012 Mar 1;6(2):396-411. DOI: 10.1177/193229681200600228

21. American Diabetes Association. Diabetes Care in the Hospital: Standards of Medical Care in Diabetes-2018. Diabetes Care. 2018 Jan;41(Suppl 1):S144-S51. DOI: 10.2337/dc18-S014

22. Joseph JI, Hipszer B, Mraovic B, Chervoneva I, Joseph M, Grunwald Z. Clinical need for continuous glucose monitoring in the hospital. J Diabetes Sci Technol. 2009 Nov 1;3(6):1309-18. DOI: 10.1177/193229680900300611

23. Bailey T, Bode BW, Christiansen MP, Klaff LJ, Alva S. The Performance and Usability of a Factory-Calibrated Flash Glucose Monitoring System. Diabetes Technol Ther. 2015 Nov;17(11):787-94. DOI: 10.1089/dia.2014.0378

24. Food and Drug Administration. iPro2 Continuous Glucose Monitoring (CGM) System 2016. https://www.accessdata.fda.gov/cdrh_docs/pdf15/P150029B.pdf

25. Food and Drug Administration. Freestyle Libre Pro Flash Glucose Monitoring System 2016. https://www.accessdata.fda.gov/cdrh_docs/pdf15/P150021B.pdf

26. Nakamura K, Balo A. The Accuracy and Efficacy of the Dexcom G4 Platinum Continuous Glucose Monitoring System. J Diabetes Sci Technol. 2015 Mar 23;9(5):1021-6. DOI: 10.1177/1932296815577812

27. Food and Drug Administration Advisory Panel Votes to Recommend Non-Adjunctive Use of Dexcom G5 Mobile CGM. Diabetes Technol Ther. 2016 Aug;18(8):512-6. DOI: 10.1089/dia.2016.07252.mr

28. Gomez AM, Henao Carrillo DC, Munoz Velandia OM. Devices for continuous monitoring of glucose: update in technology. Med Devices (Auckl). 2017 10:215-24. DOI: 10.2147/MDER.S110121

29. Thabit H, Leelarathna L, Wilinska ME, Elleri D, Allen JM, Lubina-Solomon A, et al. Accuracy of Continuous Glucose Monitoring During Three Closed-Loop Home Studies Under Free-Living Conditions. Diabetes Technol Ther. 2015 Nov;17(11):801-7. DOI: 10.1089/dia.2015.0062

30. Boscari F, Galasso S, Acciaroli G, Facchinetti A, Marescotti MC, Avogaro A, et al. Head-to-head comparison of the accuracy of Abbott FreeStyle Libre and Dexcom G5 mobile. Nutr Metab Cardiovasc Dis. 2018 Apr;28(4):425-7. DOI: 10.1016/j.numecd.2018.01.003

31. Stone MP, Agrawal P, Chen X, Liu M, Shin J, Cordero TL, et al. Retrospective Analysis of 3-Month Real-World Glucose Data After the MiniMed 670G System Commercial Launch. Diabetes Technol Ther. 2018 Oct;20(10):689-92. DOI: 10.1089/dia.2018.0202

32. Foster NC, Miller KM, Tamborlane WV, Bergenstal RM, Beck RW, Network TDEC. Continuous Glucose Monitoring in Patients With Type 1 Diabetes Using Insulin Injections. Diabetes Care. 2016 Jun;39(6):e81-2. DOI: 10.2337/dc16-0207

33. Beck RW, Riddlesworth T, Ruedy K, Ahmann A, Bergenstal R, Haller S, et al. Effect of Continuous Glucose Monitoring on Glycemic Control in Adults With Type 1 Diabetes Using Insulin Injections: The DIAMOND Randomized Clinical Trial. JAMA. 2017 Jan 24;317(4):371-8. DOI: 10.1001/jama.2016.19975

34. Lind M, Polonsky W, Hirsch IB, Heise T, Bolinder J, Dahlqvist S, et al. Continuous Glucose Monitoring vs Conventional Therapy for Glycemic Control in Adults With Type 1 Diabetes Treated With Multiple Daily Insulin Injections: The GOLD Randomized Clinical Trial. JAMA. 2017 Jan 24;317(4):379-87. DOI: 10.1001/jama.2016.19976

35. Jamiolkowska M, Jamiolkowska I, Luczynski W, Tolwinska J, Bossowski A, Glowinska Olszewska B. Impact of Real-Time Continuous Glucose Monitoring Use on Glucose Variability and Endothelial Function in Adolescents with Type 1 Diabetes: New Technology-New Possibility to Decrease Cardiovascular Risk? J Diabetes Res. 2016 2016:4385312.

36. Gomez AM, Alfonso-Cristancho R, Orozco JJ, Lynch PM, Prieto D, Saunders R, et al. Clinical and economic benefits of integrated pump/CGM technology therapy in patients with type 1 diabetes in Colombia. Endocrinol Nutr. 2016 Nov;63(9):466-74. DOI: 10.1016/j.endonu.2016.05.011

37. Bolinder J, Antuna R, Geelhoed-Duijvestijn P, Kroger J, Weitgasser R. Novel glucose-sensing technology and hypoglycaemia in type 1 diabetes: a multicentre, non-masked, randomised controlled trial. Lancet. 2016 Nov 5;388(10057):2254-63. DOI: 10.1016/S0140-6736(16)31535-5

38. Danne T, Nimri R, Battelino T, Bergenstal RM, Close KL, DeVries JH, et al. International Consensus on Use of Continuous Glucose Monitoring. Diabetes Care. 2017 Dec;40(12):1631-40. DOI: 10.2337/dc17-1600

39. Adolfsson P, Parkin CG, Thomas A, Krinelke LG. Selecting the Appropriate Continuous Glucose Monitoring System a Practical Approach. Eur Endocrinol. 2018 Apr;14(1):24-9. DOI: 10.17925/EE.2018.14.1.24

40. DuBose JJ, Inaba K, Branco BC, Barmparas G, Lam L, Teixeira PG, et al. Discrepancies between capillary glucose measurements and traditional laboratory assessments in both shock and non-shock states after trauma. J Surg Res. 2012 Dec;178(2):820-6. DOI: 10.1016/j.jss.2012.04.003

41. Ellis MF, Benjamin K, Cornell M, Decker K, Farrell D, McGugan L, et al. Suitability of capillary blood glucose analysis in patients receiving vasopressors. Am J Crit Care. 2013 Sep;22(5):423-9. DOI: 10.4037/ajcc2013692

42. Boom DT, Sechterberger MK, Rijkenberg S, Kreder S, Bosman RJ, Wester JP, et al. Insulin treatment guided by subcutaneous continuous glucose monitoring compared to frequent point-of-care measurement in critically ill patients: a randomized controlled trial. Crit Care. 2014 Aug 20;18(4):453. DOI: 10.1186/s13054-014-0453-9

43. Bochicchio GV, Hipszer BR, Magee MF, Bergenstal RM, Furnary AP, Gulino AM, et al. Multicenter Observational Study of the First-Generation Intravenous Blood Glucose Monitoring System in Hospitalized Patients. J Diabetes Sci Technol. 2015 Jul;9(4):739-50. DOI: 10.1177/1932296815587939

44. Yamashita K, Okabayashi T, Yokoyama T, Yatabe T, Maeda H, Manabe M, et al. Accuracy and reliability of continuous blood glucose monitor in post-surgical patients. Acta Anaesthesiol Scand. 2009 Jan;53(1):66-71. DOI: 10.1111/j.1399-6576.2008.01799.x

45. Munekage M, Yatabe T, Sakaguchi M, Kitagawa H, Tamura T, Namikawa T, et al. Comparison of subcutaneous and intravenous continuous glucose monitoring accuracy in an operating room and an intensive care unit. J Artif Organs. 2016 Jun;19(2):159-66. DOI: 10.1007/s10047-015-0877-2

46. Shephard M, Shephard A, McAteer B, Regnier T, Barancek K. Results from 15years of quality surveillance for a National Indigenous Point-of-Care Testing Program for diabetes. Clin Biochem. 2017 Dec;50(18):1159-63. DOI: 10.1016/j.clinbiochem.2017.07.007

47. Biethman RK, Pandarakalam C, Garcia MN, Whitener S, Hildebolt CF. Screening for Diabetes in a Dental School Clinic to Assess Interprofessional Communication Between Physicians and Dental Students. J Dent Educ. 2017 Sep;81(9):1062-7. DOI: 10.21815/JDE.017.059

48. Whitley HP, Hanson C, Parton JM. Systematic Diabetes Screening Using Point-of-Care HbA1c Testing Facilitates Identification of Prediabetes. Ann Fam Med. 2017 Mar;15(2):162-4. DOI: 10.1370/afm.2035

49. Paknikar S, Sarmah R, Sivaganeshan L, Welke A, Rizzo A, Larson K, et al. Long-Term Performance of Point-of-Care Hemoglobin A1c Assays. J Diabetes Sci Technol. 2016 Nov;10(6):1308-15. DOI: 10.1177/1932296816645362

50. Whitley HP, Yong EV, Rasinen C. Selecting an A1C Point-of-Care Instrument. Diabetes Spectr. 2015 Aug;28(3):201-8. DOI: 10.2337/diaspect.28.3.201

51. National Glycohemoglobin Standardization Program homepage http://www.ngsp.org.

52. Ferenczi A, Reddy K, Lorber DL. Effect of immediate hemoglobin A1c results on treatment decisions in office practice. Endocr Pract. 2001 Mar-Apr;7(2):85-8. DOI: 10.4158/EP.7.2.85

53. Zhou R, Wang W, Song ZX, Tong Q, Wang QT. Evaluation of a new hemoglobin A1c analyzer for point-of-care testing. J Clin Lab Anal. 2018 Jan; 32(1) DOI: 10.1002/jcla.22172

54. Bergenstal RM, Gal RL, Connor CG, Gubitosi-Klug R, Kruger D, Olson BA, et al. Racial Differences in the Relationship of Glucose Concentrations and Hemoglobin A1c Levels. Ann Intern Med. 2017 Jul 18;167(2):95-102. DOI: 10.7326/M16-2596

55. Lim S, Yu HJ, Lee S, Park H, Kwon MJ, Woo HY. Evaluation of the URiSCAN 2 ACR Strip to estimate the urine albumin/creatinine ratios. J Clin Lab Anal. 2017 Mar;32(3):1-6.

Revista Romana de Medicina de Laborator

Romanian Journal of Laboratory Medicine

Journal Information


IMPACT FACTOR 2018: 0,800
5-year IMPACT FACTOR: 0,655



CiteScore 2017: 0.31

SCImago Journal Rank (SJR) 2018: 0.194
Source Normalized Impact per Paper (SNIP) 2018: 0.306

Metrics

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 101 101 31
PDF Downloads 82 82 24